Literature DB >> 19570803

High-throughput minor histocompatibility antigen prediction.

David S DeLuca1, Britta Eiz-Vesper, Nektarios Ladas, Barbara Anna-Maria Khattab, Rainer Blasczyk.   

Abstract

MOTIVATION: Minor histocompatibility antigens (mHags) are a diverse collection of MHC-bound peptides that have immunological implications in the context of allogeneic transplantation because of their differential presence in donor and host, and thus play a critical role in the induction of the detrimental graft-versus-host disease (GvHD) or in the development of the beneficial graft-versus-leukemia (GvL) effect. Therefore, the search for mHags has implications not only for preventing GvHD, but also for therapeutic applications involving leukemia-specific T cells. We have created a web-based system, named PeptideCheck, which aims to augment the experimental discovery of mHags using bioinformatic means. Analyzing peptide elution data to search for mHags and predicting mHags from polymorphism and protein databases are the core features.
RESULTS: Comparison with known mHag data reveals that some but not all of the previously known mHags can be reproduced. By applying a system of filtering and ranking, we were able to produce an ordered list of potential mHag candidates in which HA-1, HA-3 and HA-8 occur in the best 0.25%. By combining single nucleotide polymorphism, protein, tissue expression and genotypic frequency data, together with antigen presentation prediction algorithms, we propose a list of the best peptide candidates which could potentially induce the GvL effect without causing GvFD. AVAILABILITY: http://www.peptidecheck.org.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19570803     DOI: 10.1093/bioinformatics/btp404

Source DB:  PubMed          Journal:  Bioinformatics        ISSN: 1367-4803            Impact factor:   6.937


  5 in total

1.  Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution.

Authors:  Ning Li; Catherine Matte-Martone; Hong Zheng; Weiguo Cui; Srividhya Venkatesan; Hung Sheng Tan; Jennifer McNiff; Anthony J Demetris; Derry Roopenian; Susan Kaech; Warren D Shlomchik
Journal:  Blood       Date:  2011-09-13       Impact factor: 22.113

Review 2.  Making the genomic leap in HCT: application of second-generation sequencing to clinical advances in hematopoietic cell transplantation.

Authors:  Yun R Li; John E Levine; Hakon Hakonarson; Brendan J Keating
Journal:  Eur J Hum Genet       Date:  2013-11-20       Impact factor: 4.246

3.  Anti-thymocyte globulin for conditioning in matched unrelated donor hematopoietic cell transplantation provides comparable outcomes to matched related donor recipients.

Authors:  D A Portier; R T Sabo; C H Roberts; D S Fletcher; J Meier; W B Clark; M C Neale; M H Manjili; J M McCarty; H M Chung; A A Toor
Journal:  Bone Marrow Transplant       Date:  2012-05-14       Impact factor: 5.483

Review 4.  Bone Marrow GvHD after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Martin Szyska; Il-Kang Na
Journal:  Front Immunol       Date:  2016-03-30       Impact factor: 7.561

Review 5.  The Connection Between Minor H Antigens and Neoantigens and the Missing Link in Their Prediction.

Authors:  Tuna Mutis; Anastasia Xagara; Robbert M Spaapen
Journal:  Front Immunol       Date:  2020-06-24       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.